UNSPSC 51111617: Gemcitabine

This classification denotes a ribonucleotide reductase inhibitor and pyrimidine antagonist with the molecular formula C9H11F2N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B76N6SBZ8R, chemically known as 2-deoxy-.beta.-d-2,2-difluorocytidine but generally known as gemcitabine, which bears US NIH Compound Identifier 60750. European Medicines Agency schedules Gemcitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07892MIG.

UNSPSC 51111617 Gemcitabine is a Commodity code identifying a specific chemotherapy pharmaceutical product that state and local governments procure primarily through pharmacy benefit programs and health plan administration. The Texas Health and Human Services Commission's Request for Information HHS0017013, posted April 3, 2026, demonstrates current state procurement interest in establishing direct-to-manufacturer prescription channels outside traditional pharmacy benefit manager and group purchasing organization intermediaries. State and local buying under this code centers on chemotherapy drug sourcing for employee health plans, Medicaid programs, and public health systems; the recent Texas activity signals a shift toward direct contracting models that negotiate net pricing without traditional rebate structures and potentially incorporate value-based or outcomes-based payment arrangements. Issuing bodies soliciting chemotherapy pharmaceuticals include state health departments and health plan administrators rather than counties, cities, or school districts, reflecting the concentration of pharmaceutical procurement authority within state-level health and human services agencies.

The source supports activity in Texas, where the state's effort to evaluate direct-to-manufacturer prescription fulfillment represents emerging procurement strategy development rather than established high-volume purchasing patterns. The Texas HHS RFI does not yet commit to contract values, quantities, or timelines; it functions as market intelligence gathering to inform future formal solicitations. No other recent state or local opportunities for gemcitabine procurement appear in the available record, suggesting that this Commodity code sees limited recent solicitation activity at the state and local level, or that pharmaceutical procurement in this category flows primarily through established standing agreements and cooperative purchasing vehicles rather than through discrete competitive procurements posted as RFPs, RFQs, or ITBs.